Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Mar 8:10:626.
doi: 10.3332/ecancer.2016.626. eCollection 2016.

Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments

Rajitha Lokadasan  1 , Francis V James  2 , Geetha Narayanan  1 , Pranab K Prabhakaran  1
Affiliations
Review

Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments

Rajitha Lokadasan et al. Ecancermedicalscience. .

Abstract

Epithelial ovarian cancer (EOC) remains a clinical challenge and there is a need to optimise the currently available treatment and to urgently develop new therapeutic strategies. Recently, there has been improved understanding of the molecular characteristics and tumour microenvironment of ovarian cancers. This has facilitated the development of various targeted agents used concurrently with chemotherapy or as maintenance. Most of the studies have explored the tumour angiogenesis pathways. In phase-III trials, bevacizumab showed a statistically significant improvement in progression-free survival, although there was no improvement in overall survival in selected high-risk cases. Although several multi-targeted tyrosine kinase inhibitors were found to be useful, the toxicity and survival benefit has to be weighed. Poly ADP ribose polymerase (PARP) inhibitors have been another marvellous molecule found to be effective in breast cancer 1, early onset (BRCA)-positive ovarian cancers. Several newer molecules targeting Her 2, Wee tyrsine kinases, PIP3/AKT/mTR-signalling pathways, folate receptors are under development and may provide additional opportunities in the future. This article focuses on the targeted agents that have successfully paved the way in the management of epithelial ovarian cancer and the newer molecules that may offer therapeutic opportunities in the future.

Keywords: PARP inhibitors; angiogenesis; bevacizumab; epithelial ovarian cancer; targeted agents.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. VEGF family and receptors.
Figure 2.
Figure 2.. Sites of action of various antiangiogenesis agents.
Figure 3.
Figure 3.. Concept of synthetic lethality.
See this image and copyright information in PMC

References

    1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012: Globocan 2012. Int J Cancer. 2015;136(5):E359–86. doi: 10.1002/ijc.29210. - DOI - PubMed
    1. [6th August 2015]. Ovarian cancer survival statistics [Internet] Cancer Research UK Available at: http://www.cancerresearchuk.org/health-professional/cancer-statistics/st....
    1. Rebbeck TR, Mitra N, Wan F, et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015;313(13):1347–1361. doi: 10.1001/jama.2014.5985. - DOI - PMC - PubMed
    1. Ingham SL, Warwick J, Buchan I, et al. Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2. J Med Genet. 2013;50(6):368–372. doi: 10.1136/jmedgenet-2013-101607. - DOI - PubMed
    1. Heintz APM, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet. 2006;95(Suppl 1):S161–S192. doi: 10.1016/S0020-7292(06)60033-7. - DOI - PubMed

LinkOut - more resources